StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Perspective Therapeutics's profit margin for the twelve months ending Jun 30, 2022 was -67.4%. For fiscal 2022 it was -67.4%, against -33.7% the year before. The highest annual figure on record is -33.7% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2022Jun 30, 2022-67.4%−33.7
FY2021Jun 30, 2021-33.7%+1.9
FY2020Jun 30, 2020-35.6%+34.7
FY2019Jun 30, 2019-70.3%+42.8
FY2018Jun 30, 2018-113.1%+16.3
FY2017Jun 30, 2017-129.4%−30.6
FY2016Jun 30, 2016-98.8%−18.9
FY2015Jun 30, 2015-79.9%+61.3
FY2014Jun 30, 2014-141.2%−56.0
FY2013Jun 30, 2013-85.2%−16.4
FY2012Jun 30, 2012-68.8%−14.5
FY2011Jun 30, 2011-54.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2022CQ2 2022Jun 30, 2022-83.0%−43.8
Q3 FY2022CQ1 2022Mar 31, 2022-46.3%−17.6
Q2 FY2022CQ4 2021Dec 31, 2021-57.0%−20.2
Q1 FY2022CQ3 2021Sep 30, 2021-87.5%−57.6
Q4 FY2021CQ2 2021Jun 30, 2021-39.2%+13.0
Q3 FY2021CQ1 2021Mar 31, 2021-28.7%−9.7
Q2 FY2021CQ4 2020Dec 31, 2020-36.8%+3.9
Q1 FY2021CQ3 2020Sep 30, 2020-29.9%+5.3
Q4 FY2020CQ2 2020Jun 30, 2020-52.1%+4.8
Q3 FY2020CQ1 2020Mar 31, 2020-18.9%+39.7
Q2 FY2020CQ4 2019Dec 31, 2019-40.7%+33.6
Q1 FY2020CQ3 2019Sep 30, 2019-35.2%+61.3
Q4 FY2019CQ2 2019Jun 30, 2019-56.9%+89.3
Q3 FY2019CQ1 2019Mar 31, 2019-58.6%+26.1
Q2 FY2019CQ4 2018Dec 31, 2018-74.3%+21.0
Q1 FY2019CQ3 2018Sep 30, 2018-96.5%+31.1
Q4 FY2018CQ2 2018Jun 30, 2018-146.2%−10.8
Q3 FY2018CQ1 2018Mar 31, 2018-84.7%+21.4
Q2 FY2018CQ4 2017Dec 31, 2017-95.2%+45.8
Q1 FY2018CQ3 2017Sep 30, 2017-127.7%+10.9
Q4 FY2017CQ2 2017Jun 30, 2017-135.3%−29.5
Q3 FY2017CQ1 2017Mar 31, 2017-106.1%−6.3
Q2 FY2017CQ4 2016Dec 31, 2016-141.1%−30.7
Q1 FY2017CQ3 2016Sep 30, 2016-138.6%−57.8
Q4 FY2016CQ2 2016Jun 30, 2016-105.8%−28.6
Q3 FY2016CQ1 2016Mar 31, 2016-99.7%−17.4
Q2 FY2016CQ4 2015Dec 31, 2015-110.3%–
Q1 FY2016CQ3 2015Sep 30, 2015-80.8%–
Q4 FY2015CQ2 2015Jun 30, 2015-77.2%–
Q3 FY2015CQ1 2015Mar 31, 2015-82.3%–

More Perspective Therapeutics figures

See a number that looks wrong?